NVE Corporation NVEC

Set alert

Price alert · NVEC

All alert types
77.58 USD -4.40 -5.37%

At close · Oct 30

76.80 -0.78 -1.01%

After hours · Oct 30, 4:00 PM ET

Bid
77.44 × 2
Ask
77.61 × 2
76.41 Day range 80.41
57.42 52-week range 134.21
YTD
+30.76%
1 year
+13.42%
Open
78.90
Prev close
81.98
Mkt cap
375.80M
Vol
116.92K
Avg vol
129.90K
EPS
3.69
P/E
21.02
Div yield
5.16%
More statistics
Low
76.41
High
80.41
Forward P/E
28.59
Beta
1.13
Short ratio
5.61
Inst. own
69.61%
Dividend
4.00
Ex-div date
Nov 3, 2024
Earnings
Jan 15, 2025
50-d avg
78.00
200-d avg
79.04
1y target
0.00

MAX chart

Chart tools
Interval

Chart is warming up

The all-time price history for NVEC has not been loaded yet. Try again in a moment.

Discussion (2)

Sign in to join the discussion

VICKY HANUKA NVEC 3 years ago #1

$PTC Therapeutics(PTCT.US)$ ?????????????? Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi -- Royalty Pharma purchases a portion of royalties on Roche's Evrysdi for
$1.0 billion upfront
-- PTC Therapeutics has option to sell rest of royalty for up to $500
million; Royalty Pharma has option to buy half of rest of royalty for up
to $250 million
-- Transaction expected to enhance long-term Adjusted Cash Receipts growth
(non-GAAP)
-- Royalty Pharma to host conference call today, Thursday, October 19 at
9:00am EDT
NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. to acquire additional royalties on Roche's Evrysdi for $1.0 billion upfront. The agreement includes options for PTC to sell up to all of its retained royalties on Evrysdi for up to $500 million or for Royalty Pharma to acquire half of such retained royalties for up to $250 million at a later date.